DOPR

Discovery

DOPR was first documented by Alexander Shulgin, who synthesized it as part of his systematic exploration of 4-substituted 2,5-dimethoxyamphetamines. Secondary sources place the initial characterization around 1970,^[7][8] though the earliest verifiable co-authored paper on DOx propyl analogs appeared in 1977.^[9] Shulgin's 1991 book PiHKAL: A Chemical Love Story provided the only published human bioassay data — dose range, duration, and qualitative effect descriptions — as entry #71.^[2]

Scientific significance

Within the DOx class, DOPR occupied a marginal position for decades. While DOI became a standard radioligand and DOB and DOC gained broader recognition, DOPR remained known primarily to PiHKAL readers and specialist chemists. Its pharmacological significance was established only retrospectively — first by foundational work on directional lipophilicity in 1977,^[9] then by modern studies confirming it as the most potent 4-alkyl DOx homolog at 5-HT₂A receptors.^[1]

Modern research

DOPR's research revival began in 2025, when Noback et al. demonstrated that sub-psychedelic doses enhance effortful motivation in mice — separating pro-motivational from hallucinogenic effects by approximately tenfold.^[3] Luethi et al. (2026) subsequently confirmed its position as the in vitro 5-HT₂A potency leader among DOx 4-alkyl homologues.^[1] No clinical trials have been registered as of 2026.^[3]

Structural class

DOPR belongs to the DOx series — 2,5-dimethoxy-4-substituted amphetamines — a family of phenethylamine psychedelics. The molecule carries methoxy groups at the 2- and 5-positions of the phenyl ring, an n-propyl chain at the 4-position, and an alpha-methyl group on the aminoethyl side chain.

The alpha-methyl group distinguishes DOx amphetamines from their 2C-X phenethylamine counterparts and confers resistance to monoamine oxidase breakdown, contributing to the class's characteristically long durations.^[10] DOPR is positioned between DOET (4-ethyl) and the longer-chain homologues in the DOx structural lineage.

Molecular properties

The hydrochloride salt has a melting point of 182.5–183°C.^[2] No published data on solubility or storage stability have been identified.

Stereochemistry

The alpha-methyl group creates one chirality center, yielding (R)- and (S)-enantiomers. Available DOPR is the racemic mixture.^[11] Within the DOx class, the (R)-enantiomer generally shows higher activity at 5-HT₂A receptors,^[10] but no DOPR-specific enantioselectivity studies have been published.

Structure-activity relationships

DOPR sits at a critical inflection point in DOx structure-activity work. The n-propyl chain represents the optimal 4-alkyl length for psychedelic potency — activity drops sharply with longer or branched substituents.^[12] Foundational work by Nichols, Shulgin, and Dyer (1977) established that directional lipophilicity of the 4-substituent drives potency in the series.^[9]

Subsequent research confirmed that lipophilic 4-position substituents generally enhance 5-HT₂A affinity.^[13][14] The propyl group achieves the right balance between sufficient lipophilicity for strong receptor binding and appropriate molecular geometry for optimal engagement — a balance lost when the chain extends to butyl or amyl.

Mechanism of action

DOPR is a potent full agonist at serotonin 5-HT₂A and 5-HT₂C receptors — the principal targets mediating its psychedelic effects.^[1][8] It shows negligible activity at 5-HT₁ receptor subtypes, and its potency at 5-HT₂B receptors is reported as more than 25-fold lower than at 5-HT₂A.^[8]

Receptor activation triggers a signaling cascade through Gq/G₁₁ proteins, driving calcium release inside cells. DOx amphetamines produce higher intrinsic activity at 5-HT₂A than their 2C-X phenethylamine counterparts — a distinction attributed to the alpha-methyl group on the side chain.^[10]

Downstream of acute activation, DOx-class agonists regulate BDNF (BDNF) expression in a region-specific pattern: decreased in hippocampal circuits and increased in cortical areas. Both effects are blocked by the selective 5-HT₂A antagonist ketanserin, confirming receptor specificity.^[15]

Pharmacokinetics

No human pharmacokinetic studies exist for DOPR. All characterization below is inferred from class-level data on structurally related DOx compounds.

Oral administration is the only documented route. Onset is slow, with threshold effects appearing approximately 90 minutes after ingestion.^[2] Duration extends to 20–30 hours — exceptionally long for a serotonergic psychedelic and substantially longer than LSD (approximately 12 hours) or psilocybin (approximately 6 hours).^[2]

Three pharmacological factors likely explain this extreme duration: high lipophilicity from the propyl substituent favoring sustained tissue distribution; the alpha-methyl group retarding enzymatic breakdown; and prolonged receptor occupancy characteristic of DOx agonists.^[8]

Rodent data indicate that DOPR achieves the highest brain-to-plasma ratio among DOx 4-alkyl homologues, suggesting favorable blood-brain barrier penetration.^[8] citation needed DOx compounds are metabolized primarily via O-demethylation at the 2- and 5-methoxy positions.^[4] Peak plasma concentration, half-life, bioavailability, and metabolite identification remain entirely uncharacterized in humans.

Where it acts

No direct neuroimaging or electrophysiology data exist for DOPR. Its mechanism — potent 5-HT₂A full agonism — places it among compounds that disrupt thalamocortical gating in the prefrontal cortex, where 5-HT₂A receptors are concentrated on layer V pyramidal neurons.^[16] In studies of related psychedelics, this disruption reduces default mode network integrity and increases global neural connectivity — patterns linked to ego dissolution and expanded associative thinking.

DOPR also modulates BDNF expression in a region-specific pattern: suppression in hippocampal circuits and enhancement in cortical areas.^[15] This bidirectional regulation may relate to the dual quality of psychedelic states — disruption of habitual processing alongside novel cognitive openness.

Why it matters

Two features make DOPR theoretically interesting. Its extreme duration raises the question of whether sustained 5-HT₂A activation produces qualitatively different brain dynamics than shorter-acting psychedelics — an untested hypothesis with implications for the REBUS (Relaxed Beliefs Under Psychedelics) model of psychedelic action.

Separately, DOPR's demonstrated pro-motivational effects at sub-psychedelic doses^[3] suggest that low-level 5-HT₂A activation can modulate effort-based decision-making without full perceptual disruption. This tenfold dose separation between motivation and hallucination challenges all-or-nothing models of 5-HT₂A function and aligns with the psychoplastogen hypothesis — that these compounds promote structural brain changes via neurotrophin signaling.^[16][17]

Toxicity

No lethal dose, controlled toxicity study, or human adverse event report specific to DOPR has been published. The toxicological profile rests entirely on class-level evidence from structurally related DOx compounds.

• Agitation and aggressive behavior
• Prolonged hallucinations
• Rapid heart rate
• Dangerous overheating
• Seizures
• Muscle breakdown (particularly in severe cases with agitation and overheating)

Symptoms may persist for up to 33 hours in DOx poisoning cases. safety citation needed

Psychological risks

No controlled data on DOPR-specific psychological adverse events exist. Class-level risks include:

• Acute distress: anxiety, panic, and paranoid thinking may occur at any dose, modulated by set, setting, and individual vulnerability. The extended duration increases the period of exposure and undermines the reassurance that "it will end soon."

• Psychotic episodes: Prolonged psychotic states have been reported with DOx compound use, particularly at high doses or in individuals with predisposing conditions.^[4]

• Hallucinogen persisting perception disorder (HPPD): No DOPR-specific prevalence data exist. HPPD has been associated with serotonergic psychedelic use broadly.

• Sleep deprivation: insomnia lasting into the following day was documented by Shulgin.^[2] Extended sleeplessness compounds cognitive impairment, emotional lability, and psychosis risk.

Tolerance and dependence

Cross-tolerance is expected between DOPR and other 5-HT₂A agonists (LSD, psilocybin, mescaline, other DOx compounds).^[18] Standard guidance suggests 3–5 days between psychedelic doses for tolerance to reset; given DOPR's 20–30-hour duration, longer intervals may be appropriate.

Drug interactions

No DOPR-specific interaction studies exist. All data below are class-level inferences.

SSRIs/SNRIs: Chronic SSRI use may reduce DOPR's effects via receptor downregulation. Serotonin syndrome risk is theoretically elevated but poorly characterized for DOx compounds specifically.

Lithium: Contraindicated with serotonergic psychedelics as a class. Lithium lowers seizure threshold and increases serotonin syndrome risk. safety citation needed

mGlu₂/₃ agonists: Chronic treatment with these compounds diminishes behavioral responses to 5-HT₂A agonist phenethylamines.^[20]

Contraindications

No DOPR-specific contraindication data exist. The following are inferred from the DOx class:

• Psychotic spectrum disorders: 5-HT₂A agonists may trigger or worsen psychotic episodes. Absolute contraindication.
• Bipolar disorder: Risk of manic episode. DOPR's extended duration compounds this risk through prolonged mood destabilization.
• Heart conditions: Sustained sympathomimetic effects over 20–30 hours present risk for individuals with pre-existing cardiovascular disease.
• Seizure disorders: DOx-class toxicity includes seizure risk; individuals with lowered seizure threshold face elevated risk.
• Concurrent MAOI use: Absolute contraindication due to serotonin syndrome risk.
• Concurrent lithium use: Absolute contraindication due to seizure and serotonin syndrome risk.
• Pregnancy: No reproductive toxicity data exist. Serotonergic psychedelics are contraindicated in pregnancy as a class. safety citation needed

DOPR is not scheduled under any United Nations drug convention.^[4] National regulation varies, with some jurisdictions applying explicit scheduling, others relying on structural analog provisions, and several maintaining no specific classification.

Analogue act considerations

DOPR's structural relationship to DOM (Schedule I in the United States) is the primary legal vulnerability. The Federal Analogue Act treats structural analogs of Schedule I or II substances as Schedule I when intended for human consumption. DOPR shares the 2,5-dimethoxyamphetamine scaffold with DOM and produces psychedelic effects through the same receptor mechanism. Sale as an analytical reference standard or research chemical may fall outside this provision, though enforcement varies.